Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
Alistair Nichol, Craig French, Lorraine Little...
https://pubmed.ncbi.nlm.nih.gov/26452709/Actively Recruiting
Led by Australian and New Zealand Intensive Care Research Centre · Updated on 2025-07-16
2500
Participants Needed
41
Research Sites
34 weeks
Total Duration
Researchers are evaluating epoetin alfa, a medication related to erythropoiesis stimulating agents, in critically ill trauma patients who require mechanical ventilation in intensive care units ICUs. This phase III, randomized, double-blind trial aims to see if epoetin alfa can reduce death rates and severe disability six months after injury. The study involves 2500 patients admitted to ICUs with primary trauma diagnoses from centers in Australia, New Zealand, Europe, and Saudi Arabia. Participants will receive either epoetin alfa 40,000 IU or a placebo sodium chloride 0.9% by subcutaneous injection on Study Days 1 and 8 while in the ICU. Treatment is administered during their ICU stay, and patients are randomly assigned to one of these two groups. The study is designed to compare the effects of epoetin alfa against placebo in this critically ill population. During the study, patients will be monitored for survival and disability outcomes using tools like the World Health Organization Disability Assessment Schedule WHODAS 2.0 at six months. Other outcomes include mortality at different time points and thrombotic vascular events. Data on clinical status, adverse events, and safety will also be collected. The total participation length includes ICU stay and follow-up assessments up to six months after injury.
CONDITIONS
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
V
Vicki Papanikolaou
S
Sian Donnelly
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Australian and New Zealand Intensive Care Research Centre
Lead Sponsor
University College Dublin
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 24 hours after injury before enrollment
Participants are screened for eligibility to participate in the trial.
1 screening visit (in-person)
Duration - Study Days 1 and 8 during the ICU stay
Participants receive either epoetin alfa or placebo by subcutaneous injection during their intensive care unit stay.
2 visits (in-person injections on Days 1 and 8)
Duration - 6 months
Participants are followed for assessment of mortality and disability outcomes up to 6 months after treatment.
Follow-up visits as per study schedule (visit frequency not specified)
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alistair Nichol, Craig French, Lorraine Little...
https://pubmed.ncbi.nlm.nih.gov/26452709/Australian and New Zealand Intensive Care Research Centre
Lead Sponsor
University College Dublin
Collaborating Sponsor